Cencora, Inc. (NYSE:COR) Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its holdings in Cencora, Inc. (NYSE:COR) by 6.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 39,462 shares of the company’s stock after buying an additional 2,351 shares during the period. Crossmark Global Holdings Inc.’s holdings in Cencora were worth $8,866,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Insight Wealth Strategies LLC boosted its stake in Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after acquiring an additional 11,232 shares during the period. Cerity Partners LLC grew its stake in Cencora by 10.1% during the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after buying an additional 3,610 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its position in Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after buying an additional 2,928 shares during the period. Portfolio Design Labs LLC acquired a new stake in Cencora in the third quarter worth $1,404,000. Finally, Mackenzie Financial Corp lifted its stake in Cencora by 9.9% in the second quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock valued at $18,250,000 after buying an additional 7,266 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Evercore ISI boosted their price objective on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Barclays raised their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Leerink Partners reduced their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $275.60.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 in the last quarter. Insiders own 15.80% of the company’s stock.

Cencora Trading Up 1.3 %

Shares of Cencora stock opened at $245.21 on Wednesday. The business has a fifty day simple moving average of $237.38 and a 200-day simple moving average of $234.15. The firm has a market cap of $47.39 billion, a price-to-earnings ratio of 32.65, a price-to-earnings-growth ratio of 1.51 and a beta of 0.49. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a dividend of $0.55 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora’s dividend payout ratio (DPR) is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.